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321 Stromal cell–derived factor and granulocyte-monocyte colony-stimulating
factor form a combined neovasculogenic therapy for ischemic
cardiomyopathy
Y. Joseph Woo, MD, Todd J. Grand, BS, Mark F. Berry, MD, Pavan Atluri, MD,
Mireille A. Moise, MD, Vivian M. Hsu, BA, Jeffrey Cohen, Omar Fisher, BSE,
Jeffrey Burdick, BS, Matthew Taylor, BS, Suzanne Zentko, MD, George Liao, MB, Max Smith,
Steve Kolakowski, MD, Vasant Jayasankar, MD, Timothy J. Gardner, MD, and
H. Lee Sweeney, PhD, Philadelphia, Pa
Global bone marrow stimulation with granulocyte-monocyte colony-stimulating factor to induce
endothelial progenitor cell (EPC) proliferation combined with stromal cell–derived
factor–targeted myocardial EPC chemokinesis was investigated as a vasculogenic therapy for
ischemic cardiomyopathy. Compared with control animals, experimental animals manifested
significantly increased neovasculogenesis, attenuated adverse ventricular remodeling, and
improved ventricular function.
330 Differential cardiac gene expression during cardiopulmonary bypass:
Ischemia-independent upregulation of proinflammatory genes
Mihai V. Podgoreanu, MD, Gregory A. Michelotti, PhD, Yukie Sato, MD,
Michael P. Smith, MSc, Simon Lin, MD, Richard W. Morris, PhD, Hilary P. Grocott, MD,
Joseph P. Mathew, MD, and Debra A. Schwinn, MD, Durham, NC
Rats exhibit a robust inflammatory response after normothermic, nonpulsatile cardiopulmonary
bypass. Myocardial inflammatory gene induction occurs after cardiopulmonary bypass, even in
the absence of ischemia-reperfusion injury.
340 Bilateral internal thoracic artery grafting with and without
cardiopulmonary bypass: Six-year clinical outcome
Antonio M. Calafiore, MD, Gabriele Di Giammarco, MD, Giovanni Teodori, MD,
Angela L. Iacò, MD, Marco Pano, MD, Marco Contini, MD, Giuseppe Vitolla, MD, and
Michele Di Mauro, MD, Torino and Chieti, Italy
We sought to evaluate the early and late results of patients who underwent off-pump or on-
pump myocardial revascularization with bilateral internal thoracic artery grafting. From
November 1994 through December 2001, 1194 (597 each group) patients were selected by
applying a propensity score. Off-pump operations can be performed safely and with a similar
quality of late results as seen after on-pump operations.
346 Phosphodiesterase type 4 inhibitor rolipram inhibits activation of monocytes
during extracorporeal circulation
Yukio Sato, MD, PhD, Yuji Hiramatsu, MD, PhD, Satoshi Homma, MD, PhD,
Makiko Sato, MD, Shyoko Sato, Shunsuke Endo, MD, PhD, and Yasunori Sohara, MD, PhD,
Tochigi and Tsukuba, Japan
The effect of rolipram, a selective phosphodiesterase type 4 inhibitor, on monocytes during
simulated extracorporeal circulation was examined. Rolipram reduced the changes in CD11b
and L-selectin expression of monocytes and IL-6. Phosphodiesterase type 4 inhibition could be
feasible therapeutic strategy in patients undergoing CPB for preventing exaggerated
inflammatory response.
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